UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported)

October 29, 2015

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

<u>**Delaware**</u> (State of incorporation)

<u>000-20852</u> (Commission File Number) 16-1387013 (IRS Employer Identification No.)

2000 Technology Parkway, Newark, New York

(Address of principal executive offices)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

14513 (Zip Code)

(315) 332-7100

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Item 2.02 Results of Operations and Financial Condition

NEWARK, N.Y. – October 29, 2015 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of \$1.2 million on revenue of \$19.0 million for the quarter ended September 27, 2015. For the third quarter of 2014, the Company reported an operating loss of \$0.1 million on revenue of \$16.1 million.

"Through sustained execution, we delivered another quarter of profitable growth, steadily building on the revenue gain, margin expansion and positive EPS we generated for the first half of the year. On a 19% increase in revenue for the third quarter, we posted a consolidated gross margin of 31.0%, an operating margin of 6.2% and EPS of \$0.07 per share. As a result, on a year-to-date basis, we have generated \$5.3 million more in operating income on a \$10.6 million gain in revenue, clearly demonstrating our business model operating leverage," said Michael D. Popielec, Ultralife's President and Chief Executive Officer. "With our new products gaining traction and our opportunity set widening, we firmly believe our plans to produce revenue and earnings growth for 2015 are within reach."

Revenue grew 19%, or \$3.0 million, to \$19.0 million from \$16.1 million for the third quarter of 2014. Battery & Energy Products sales increased 18% to \$16.4 million compared to \$13.9 million last year, reflecting higher shipments to both Government/Defense and commercial customers. Communications Systems sales were \$2.7 million compared to \$2.1 million for the same period last year, an increase of 23%.

Gross profit grew 32% to \$5.9 million from \$4.5 million for the third quarter a year ago. As a percentage of revenue, gross profit increased 310 basis points to 31.0% from 27.9% last year, primarily reflecting favorable product mix and improved overhead absorption on higher sales volumes. Battery & Energy Products' gross margin was 29.1% compared to 27.4% last year, an increase of 170 basis points. Communications Systems' gross margin was 42.4% compared to 31.4% last year, an increase of 1,100 basis points.

Operating expenses were \$4.7 million compared to \$4.5 million for the third quarter of 2014, reflecting higher new product development spending and sales commissions. As a percentage of revenue, operating expenses improved 350 basis points to 24.8% compared to 28.3% a year ago.

The combination of increased revenue and improved gross margin drove a \$1.2 million gain in operating income. Operating income was \$1.2 million compared to an operating loss of \$0.1 million for the third quarter of 2014. Operating margin was 6.2% compared to (0.3%) for the year-earlier period.

Net income was \$1.0 million, or \$0.07 per share, compared to a net loss of (\$0.3) million, or (\$0.02) per share, for the third quarter of 2014.

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

(a) Exhibits

99.1 Press Release of Ultralife Corporation dated October 29, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ULTRALIFE CORPORATION

October 29, 2015 By: /s/ Philip A. Fain

Chief Financial Officer and Treasurer

Company Contact: <u>Ultralife Corporation</u> Philip A. Fain (315) 332-7100 <u>pfain@ulbi.com</u> Investor Relations Contact:
LHA
Jody Burfening
(212) 838-3777
jburfening@lhai.com

Ultralife Corporation Reports Third Quarter Results

NEWARK, N.Y. – October 29, 2015 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of \$1.2 million on revenue of \$19.0 million for the quarter ended September 27, 2015. For the third quarter of 2014, the Company reported an operating loss of \$0.1 million on revenue of \$16.1 million.

"Through sustained execution, we delivered another quarter of profitable growth, steadily building on the revenue gain, margin expansion and positive EPS we generated for the first half of the year. On a 19% increase in revenue for the third quarter, we posted a consolidated gross margin of 31.0%, an operating margin of 6.2% and EPS of \$0.07 per share. As a result, on a year-to-date basis, we have generated \$5.3 million more in operating income on a \$10.6 million gain in revenue, clearly demonstrating our business model operating leverage," said Michael D. Popielec, Ultralife's President and Chief Executive Officer. "With our new products gaining traction and our opportunity set widening, we firmly believe our plans to produce revenue and earnings growth for 2015 are within reach."

Third Quarter 2015 Financial Results

Revenue grew 19%, or \$3.0 million, to \$19.0 million from \$16.1 million for the third quarter of 2014. Battery & Energy Products sales increased 18% to \$16.4 million compared to \$13.9 million last year, reflecting higher shipments to both Government/Defense and commercial customers. Communications Systems sales were \$2.7 million compared to \$2.1 million for the same period last year, an increase of 23%.

Gross profit grew 32% to \$5.9 million from \$4.5 million for the third quarter a year ago. As a percentage of revenue, gross profit increased 310 basis points to 31.0% from 27.9% last year, primarily reflecting favorable product mix and improved overhead absorption on higher sales volumes. Battery & Energy Products' gross margin was 29.1% compared to 27.4% last year, an increase of 170 basis points. Communications Systems' gross margin was 42.4% compared to 31.4% last year, an increase of 1,100 basis points.

Operating expenses were \$4.7 million compared to \$4.5 million for the third quarter of 2014, reflecting higher new product development spending and sales commissions. As a percentage of revenue, operating expenses improved 350 basis points to 24.8% compared to 28.3% a year ago.

The combination of increased revenue and improved gross margin drove a \$1.2 million gain in operating income. Operating income was \$1.2 million compared to an operating loss of \$0.1 million for the third quarter of 2014. Operating margin was 6.2% compared to (0.3%) for the year-earlier period.

Net income was \$1.0 million, or \$0.07 per share, compared to a net loss of (\$0.3) million, or (\$0.02) per share, for the third quarter of 2014.

Share Repurchase Program

During the third quarter Ultralife repurchased 748,582 shares under its currently authorized 3.4 million share repurchase program, which will expire April 30, 2016. Since the inception of the share repurchase program on May 1, 2014, the Company has repurchased 2,442,191 shares.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from portable power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the company's business segments include: Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in U.S. military spending, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands) (unaudited)

ASSET	ΓS				
	Sept	ember 27,	December 31, 2014		
		2015			
Current assets:					
Cash and cash equivalents	\$	14,728	\$	17,866	
Trade accounts receivable, net		11,242		11,295	
Inventories, net		23,352		26,086	
Prepaid expenses and other current assets		2,226		1,603	
Total current assets		51,548		56,850	
Property, equipment and improvements, net		9,191		9,812	
Goodwill, intangibles and other assets		20,613		20,980	
Total assets	\$	81,352	\$	87,642	
LIABILITIES AND SHAR	EHOLDERS' EQUITY				
Current liabilities:	ф	C = CC	ф	6.006	
Accounts payable	\$	6,766	\$	6,996	
Accrued compensation and related benefits		2,398		1,725	
Accrued expenses and other current liabilities		2,334		2,490	
Total current liabilities		11,498		11,211	
Deferred income taxes and other non-current liabilities		4,679		4,518	
Total liabilities		16,177		15,729	
Shareholders' equity:					
Common stock		1,899		1,894	
Capital in excess of par value		176,402		175,940	
Accumulated deficit		(94,553)		(96,920)	
Accumulated other comprehensive loss		(750)		(467)	
Treasury stock		(17,686)		(8,420)	
Total Ultralife equity		65,312		72,027	
Noncontrolling interest		(137)		(114)	
Total shareholders' equity		65,175		71,913	
Total liabilities and shareholders' equity	\$	81,352	\$	87,642	

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands except per share amounts) (unaudited)

	Sep	Three month ptember 27, 2015	nth periods ended September 28, 2014		Nine montl September 27, 2015		h periods ended September 28, 2014	
Revenues:					-			
Battery & energy products	\$	16,390	\$	13,913	\$	48,638	\$	40,000
Communication systems		2,654		2,149		8,538		6,546
Total revenues		19,044		16,062	\$	57,176	\$	46,546
Cost of products sold:								
Battery & energy products		11,616		10,100		34,538		29,510
Communication systems		1,528		1,476		4,872		4,003
Total cost of products sold		13,144		11,576		39,410		33,513
Gross profit		5,900		4,486		17,766		13,033
Operating expenses:		1 22 4		1.014		2.017		4.010
Research and development		1,224		1,014		3,917		4,010
Selling, general and administrative		3,503		3,527		11,037		11,498
Total operating expenses		4,727		4,541		14,954		15,508
Operating income (loss)		1,173		(55)		2,812		(2,475)
Other (expense) income:								
Interest income		_		3		2		12
Interest and financing expense		(65)		(56)		(197)		(153)
Miscellaneous		70		(158)		39		(128)
Income (loss) from continuing operations before income taxes		1,178		(266)		2,656		(2,744)
Income tax provision		130		60		312		177
Net income (loss) from continuing operations		1,048		(326)		2,344		(2,921)
Loss from discontinued operations, net of tax								(61)
N. C. A.		1.040		(226)		2.244		(2.002)
Net income (loss)		1,048		(326)		2,344		(2,982)
Net (income) loss attributable to noncontrolling interest		(1)		3	_	23		13
Net income (loss) attributable to Ultralife	\$	1,047	\$	(323)	\$	2,367	\$	(2,969)
Net income (loss) per share attributable to Ultralife common shareholders – basic:								
Continuing operations	\$.07	\$	(.02)	\$.14	\$	(.17)
Discontinued operations	J	.07	ψ	(.02)	Ψ	.14	ψ	(.00)
Total	\$.07	\$	(.02)	\$.14	\$	(.17)
Net income per share attributable to Ultralife common shareholders – diluted:	<u> </u>		-	<u> </u>	<u> </u>			
Continuing operations	\$.07			\$.14		
Discontinued operations								
Total	\$.07			\$.14		
Weighted average shares outstanding – basic		15 622		17.400		16 502		17 510
Weighted average shares outstanding – diluted		15,633		17,490		16,503		17,510
weighten average shares outstanding – undten		15,740				16,550		